EVAX

Announcements

Nothing here yet

Daily updates

• Evaxion announced three-year follow-up results from its Phase 2 EVX-01 melanoma trial, showing that all evaluable patients maintained their previous clinical benefit without disease progression.Oct 19, 2026

FDA designations

Nothing here yet

News

• Evaxion reports sustained clinical responses in all patients at three-year follow-up of its Phase 2 trial of personalized cancer vaccine EVX-01Oct 19, 2026
• Evaxion expanded and refocused its R&D pipeline with EVX-05, an AI-designed off-the-shelf vaccine program for brain cancerAug 17, 2026
• Evaxion presented new preclinical data for EVX-04, an off-the-shelf vaccine for acute myeloid leukemiaJun 11, 2026
• Evaxion completed the final patient visit in the one-year extension of its Phase 2 cancer vaccine trialApr 7, 2026
• Evaxion announced positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1Nov 20, 2025